Monogram Biosciences
 | This article needs additional citations for verification. (August 2022) |
 | This article includes a list of general references, but it lacks sufficient corresponding inline citations. (May 2010) |
| Company type | LabCorp |
|---|---|
| Website | http://www.monogrambio.com/ |
Monogram Biosciences, Inc. (formerly ViroLogic Inc.) is an international biotechnology laboratory located in South
.Virologic was founded in 1996 by Daniel Capon, Ph.D., Martin Goldstein and Robert S. Capon. The company went public (NASDAQ: VLGC) in 2000.[1]
Monogram was acquired by
Laboratory Corporation of America in June 2009.[2]
References
- ^ SEC. "Monogram Biosciences, Inc. 2000 Quarterly Report 10-Q". SEC.report. p. 10. Retrieved 2020-06-22.
- ^ "LabCorp Successfully Completes Acquisition of Monogram Biosciences, Inc". Business Wire. Retrieved 28 May 2010.
External links
- Official website
- Baseline HIV Type 1 Coreceptor Tropism Predicts Disease Progression [1]
- Four Studies Affirm Significance Of Monogram's Trofile(TM) HIV Co-Receptor Tropism Assay [2]
- Accuracy of Monogram's Trofile Assay in Determining Tropism and New Tropism Assays in Development [3]
- Trofile Bests SensiTrop as Most Reliable Tropism Test [4]
- Monogram Biosciences teams up with Pfizer for HIV treatment [5]
- Monogram Biosciences Launches New "Trofile" HIV Co-receptor Tropism Test to Select Patients Eligible to User CCR5 Antagonist Maraviroc (Selzentry) [6]